Pangaea Oncology SA
MAD:PANG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pangaea Oncology SA
MAD:PANG
|
ES |
|
Schaffer Corporation Ltd
ASX:SFC
|
AU |
|
Diatreme Resources Ltd
ASX:DRX
|
AU |
|
T
|
Toba Surimi Industries Tbk Pt
IDX:CRAB
|
ID |
|
T
|
Twin Vee PowerCats Co
NASDAQ:VEEE
|
US |
|
Saunders International Ltd
ASX:SND
|
AU |
|
Wincanton PLC
LSE:WIN
|
UK |
|
Klepierre SA
PAR:LI
|
FR |
|
W
|
Whitehaven Coal Ltd
SWB:WC2
|
AU |
|
Zoom Video Communications Inc
NASDAQ:ZM
|
US |
|
S
|
SRM Entertainment Inc
NASDAQ:SRM
|
US |
|
P
|
PIERER Mobility AG
XETRA:PMAG
|
AT |
|
Honeywell International Inc
NASDAQ:HON
|
US |
|
WLM Participacoes e Comercio de Maquinas e Veiculos SA
BOVESPA:WLMM4
|
BR |
|
T
|
Tessellis SpA
MIL:TSL
|
IT |
|
Oberoi Realty Ltd
BSE:533273
|
IN |
Pangaea Oncology SA
Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona and currently employs 50 full-time employees. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona and currently employs 50 full-time employees. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
